drugset / Trial / NCT04790006
A Study of TG103 in Subjects With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this study is to assess the safety and tolerability of multiple ascending doses of TG103 in subjects with type 2 diabetes.
Timeline
- Start
- 2021-04
- Primary completion
- 2022-03
- Completion
- 2022-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TG103 | Protein / enzyme biologic | 7.5 mg | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Subject | TG103 | Protein / enzyme biologic | 22.5 mg | Subcutaneous |